JohannChristophBrandesMDPhD, FCCP
Oncology • Murfreesboro, TNHematologic Oncology, Thoracic Cancer
Physician at Tennessee Oncology, Adjunct Assistant Professor, Hematology and Medical Oncology, Emory University School of Medicine
Dr. Brandes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1840 Medical Center Pkwy
Ste 300
Murfreesboro, TN 37129Phone+1 615-848-0488Fax+1 615-904-9061
Education & Training
Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2007- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2005
- Johns Hopkins UniversityResidency, Internal Medicine, 2000 - 2003
Ruprecht Karls UniversityPhD, 2001
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1998
Certifications & Licensure
TN State Medical License 2014 - 2025
GA State Medical License 2009 - 2016
MD State Medical License 2003 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2013 Feb 13
Publications & Presentations
PubMed
- 22 citationsFollowing mitochondrial footprints through a long mucosal path to lung cancer.Santanu Dasgupta, Rex Yung, William H. Westra, David Rini, Johann C. Brandes
Plos One. 2009-08-06 - 184 citationsCancer DNA Methylation: Molecular Mechanisms and Clinical ImplicationsMichael T. McCabe, Johann C. Brandes, Paula M. Vertino
Clinical Cancer Research. 2009-06-15 - 32 citationsHuman immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy.Suchita Pakkala, Zhengjia Chen, David Rimland, Taofeek K. Owonikoko, Clifford J. Gunthel
Cancer. 2012-01-01
Press Mentions
Epilepsy Drug Lowers Head and Neck Cancer Risk by 34%February 10th, 2016
Grant Support
- CHFR as novel drug target to overcome taxane resistance in cancerElsa U Pardee Foundation2013–Present
- HDAC inhibition for Lung Cancer PreventionVHA Basic Laboratory Science Service2012–Present
- Can natural compounds augment the effects of HDAC inhibition for LC prevention?NIH2011–2012
- Targeting CHFR Through PARP-Inhibition: A Novel Strategy To Overcome Taxane Resistance in Adenocarcinomas of the LungUniting against Lung Cancer / Lungevity Foundation2009–2011
- Epigenetic predictors of response after platinum taxane based chemotherapy in NSCLCCHEST Foundation /Lungevity Foundation2009–2011
Committees
- Member, ACCP Thoracic Oncology Steering Commitee 2012 - Present
- Member, ECOG Cancer Prevention Commitee 2012 - Present
Professional Memberships
- Fellow
- Member
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
